Jeffrey Gregg
Sacramento, CANPI 1689657918
Payments from drug & device makers
Across 871 payments — averaging $1261.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1000K
- Blueprint Medicines Corporation$62K
- E.r. Squibb & Sons, L.L.C.$19K
- Novartis$9K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Roche Diagnostics Corporation$2K
- plus $3K from 5 others
Across 1 payment — averaging $1155.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1K
What the payments were for
- Consulting fees$64,7907%
- Speaking & faculty fees$686,02875%
- Travel & lodging$144,59416%
- Food & beverage$20,8932%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 756 | $999,898 |
| Blueprint Medicines Corporation | 74 | $62,330 |
| E.r. Squibb & Sons, L.L.C. | 25 | $18,806 |
| Novartis | 7 | $8,925 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $3,685 |
| Roche Diagnostics Corporation | 1 | $2,400 |
| Roche Sequencing Solutions, Inc. | 1 | $1,500 |
| Bayer | 1 | $842 |
| Foundation Medicine, Inc. | 2 | $136 |
| Eli Lilly | 1 | $95 |
| Adaptive Biotechnologies Corporation | 1 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.